Goldman Sachs
NVCR icon

Goldman Sachs’s NovoCure NVCR Stock Holding History

Goldman Sachs’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-19,000
Closed -$1.43M – 6812
2021
Q4 		$1.43M Hold
19,000
– – ﹤0.01% 4539
2021
Q3 		$2.21M Hold
19,000
– – ﹤0.01% 4106
2021
Q2 		$4.21M Hold
19,000
– – ﹤0.01% 3490
2021
Q1 		$2.51M Hold
19,000
– – ﹤0.01% 3762
2020
Q4 		$3.29M Buy
19,000
+5,000
+36% +$684K ﹤0.01% 3342
2020
Q3 		$1.56M Buy
+14,000
New +$1.12M ﹤0.01% 3751
2016
Q1 		– Sell
-30,000
Closed -$671K – 7243
2015
Q4 		$671K Buy
+30,000
New +$717K ﹤0.01% 4666

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Goldman Sachs's NVCR Position: Q2 2026 in Review

Goldman Sachs increased its NovoCure (NVCR) stake by 29% in Q2 2026, buying an estimated $3.31M and bringing the position to 963,917 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2939.

Goldman Sachs first reported a position in NVCR in Q4 2015 and has held it in 43 quarters since. The position peaked at $97M in Q3 2017. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Goldman Sachs held 963,917 shares of NovoCure worth $14.6M as of Q2 2026.
  • Goldman Sachs bought 218,482 NovoCure shares in Q2 2026, an estimated $3.31M.
  • NovoCure made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2939 holding.
  • Goldman Sachs first reported a position in NovoCure in Q4 2015 and has held it in 43 quarters since.
  • Goldman Sachs's NovoCure position peaked at $97M in Q3 2017.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.